Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Liothyronine and Levothyroxine Clear all

Conditions: Head and Neck Cancer
Interventions: azacitidine, liothyronine sodium, iodine I 131; Drug · Radiation
Lead sponsor: Lucille P. Markey Cancer Center at University of Kentucky; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hypothyroidism
Interventions: Levothyroxine, Levothyroxine Plus Liothyronine, Desiccated Thyroid Extract; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Besthesda, Maryland

Conditions: Hypothyroidism, Brain Tumor
Interventions: Levothyroxine, Liothyronine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fracture
Interventions: ibuprofen, acetamin w codeine; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 4 Years to 18 Years
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypothyroidism Primary
Interventions: Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions: Levothyroxine, Liothyronine, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Heart Defects, Congenital
Interventions: Liothyronine sodium/triiodothyronine, Cardiopulmonary bypass and cardiac surgery; Drug · Procedure
Lead sponsor: Michael Portman; Other
Eligibility: Up to 2 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Congenital Heart Defects
Interventions: Triostat, Placebo; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 5 Months
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Palo Alto, California • Seattle, Washington

Conditions: Major Depressive Disorder
Interventions: Cytomel (liothyronine); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions: Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ); Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 25 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • Seattle, Washington

Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio

Conditions: Fibromyalgia
Interventions: T3; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pregnancy Related, Thyroid
Interventions: levothyroxine; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Major Depression
Interventions: Tranylcypromine, Dextroamphetamine, Triiodothyronine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions: liothyronine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 58 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insulin Resistance, Diabetes Mellitus, Abnormal Glucose Metabolism
Interventions: Liothyronine; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

Acute Pediatric Fracture Analgesia Study

T4/T3 Therapy in Hypothyroidism

Energy Metabolism in Thyroidectomized Patients

Study of Triostat in Infants During Heart Surgery

Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Study of T3 for the Treatment of Fibromyalgia

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

Open-label Study of Liothyronine in MS

Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations